Published October 20, 2021 from 3 p.m. 05 p.m. HST|Updated 52 minutes ago
Degion, South Korea, October 20, 2021 (PRNewswire) – On. September 2, 2021, A scientific paper from GenKOre, published in the online edition of Nature Biotechnology (IF 54.9) called CRISPR / Cas12f-GE, one of the world’s leading biotechnology journals.
For effective gene treatment, it is important to get the genetic load in the patient’s body. The best way to achieve this is to use Adeno-Associated Virus (AAV) as a vector. AAV is a single-stranded DNA virus that penetrates non-dividing or non-dividing cells. AAV only multiplies when there is an auxiliary virus and therefore does not cause disease in humans. Because of these characteristics, it is an effective and practical method for transmitting avian genes to different cell types and is used as a vector in gene therapy. However, with CRISPR / Cas9 technology, the scissors gene is large and the gene is difficult to transport in the human body using the AAV carrier. As a result, the CRISPR / Cas9 clinic is as limited as gene therapy.
Built by GenKOre, the gene in the CRISPR / Cas12f-GE system is one-third of the 9, so it is a good payment for AAV shipping. GenKOre has demonstrated its potential as an effective gene therapy by improving editing efficiency. In addition to its high editing efficiency, it has proven to be as effective and safe as Gene Scissors technology when it comes to chronic shortcomings outside the target.
The hypercompact CRISPR system Cas12f-GE describes its value as a therapeutic agent, which can be widely used to provide treatment for patients suffering from chronic diseases or illnesses due to lack of basic solutions.
The new technology was successfully developed by GenKOre, a spin-off company of the South Korean government-funded Korean Research and Biotechnology (KRIBB) Research Institute.
Dr. Yong-Sam Kim“We hope that our success based on our research will lead to a revolution in genetic therapies using this genomic editing tool. And I hope security contributes.
With the successful development of CRISPR / Cas12f-GE, GenKOre plans to develop gene therapy and new products with a variety of gene scissors technology and to become a market leader in gene therapy and new plant biotechnology with other companies.
See GenKOre paper published online by Natural Biotechnology for more content https://www.nature.com/articles/s41587-021-01009-z.
GenKOre’s website is www.genkore.com.
Check out the original content to download multimedia
The above press release was courtesy of PRNewswire. The views, comments and statements contained in the press release are not supported by the Gray Media Group or the Gray Media Group, Inc.